CYP2C19 polymorphism effect on phenobarbitone. Pharmacokineties in Japanese patients with epilepsy: Analysis by population pharmacokinetics

European Journal of Clinical Pharmacology

Volumn 55, Issue 11-12, 2000, Pages 821-825

  Mamiya, K ^a,b   Hadama, A ^a   Yukawa, E ^a   Ieiri, I ^c   Otsubo, K ^c   Ninomiya, H ^b   Tashiro, N ^b   Higuchi, S ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

Author keywords

CYP2C19; Genetic polymorphism; NONMEM; Pharmacokinetics; Phenobarbitone

Indexed keywords

PHENOBARBITAL; PHENYTOIN;

ADULT; AGED; ARTICLE; DRUG DISPOSITION; DRUG METABOLISM; EPILEPSY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0034037772     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050703     Document Type: Article

References (24)

1. Yukawa E, Higuchi S, Aoyama T (1992) Influence of age and co-medication on steady-state phenobarbital serum level-dose ratios in Japanese paediatric patients. J Clin Pharm Ther 17: 249-253
2. Yukawa E, Higuchi S, Aoyama T (1992) Phenobarbitone population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. J Pharm Pharmacol 44: 755-760
3. Yukawa E, To H, Ohdo S, Higuchi S, Aoyama T (1998) Detection of a drug - drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling. Eur J Clin Pharmacol 54: 69-74
4. Anderson GD, Levy RH (1995) Phenobarbital: chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS (eds) Antiepileptic drugs, 4th edn. Raven Press, New York, pp 371-377
5. Reidenberg P, Glue P, Banfield CR, Colucci RD, Meehan JW, Radwanski E, Mojavarian P, Lin CC, Nezamis J, Guillaume M, Affrime MB (1995) Effects of felbamate on the pharmacokinetics of phenobarbital. Clin Pharmacol Ther 58: 279-287
6. Riva R, Albani F, Contin M, Baruzzi A (1996) Pharmacokinetic interaction between antiepileptic drugs. Clin Pharmacokinet 31: 470-493
7. Anderson GD (1998) A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 32: 554-563
8. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269: 15419-15422
9. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46: 594-598
10. Kaminsky LS, de Morais SMF, Faletto MB, Dunbar DA, Goldstein JA (1992) Correlation of human cytochrome P450 2C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol 43: 234-239
11. Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, Yamada H, Otsubo K, Higuchi S, Tashiro N (1998) The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult epileptic patients; studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 39: 1317-1323
12. Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S (1998) Genetic polymorphism of cytochrome P450s, CYP2C19 and CYP2C9, in a Japanese population. Ther Drug Monit 20: 243-247
13. Wang S-L, Huang J-D, Lai M-D, Tsai J-J (1995) Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5: 37-42
14. Beal SL, Sheiner LB (eds) (1992) NONMEM user's guides. NONMEM Project Group, University of California at San Francisco, San Francisco
15. Dodson KW, Rust RS (1995) Phenobarbital: absorption, distribution, and excretion. In: Levy RH, Mattson RH, Meldrum BS (eds) Antiepileptic drugs, 4th edn. Raven Press, New York, pp 379-387
16. Kutt H (1995) Phenobarbital: interaction with other drugs. In: Levy RH, Mattson RH, Meldrum BS (eds) Antiepileptic drugs, 4th edn. Raven Press, New York, pp 389-399
17. Kapetanovic IM, Kupferberg HJ, Porter RJ, Theodore W, Schulman E, Penry JK (1981) Mechanism of valproate-phenobarbital interaction in epileptic patients. Clin Pharmacol Ther 29: 480-486
18. Bernus I, Dickinson RG, Hooper WD, Eadie MJ (1994) Inhibition of phenobarbitone N-glucosidation by valproate. Br J Clin Pharmacol 38: 411-416
19. Patel IH, Levy RH, Culter RE (1980) Phenobarbital-valproic acid interaction in normal man. Clin Pharmacol Ther 27: 515-521
20. Banfield CR, Levy RH (1995) Felbamate: interaction with other drugs. In: Levy RH, Mattson RH, Meldrum BS (eds) Antiepileptic drugs, 4th edn. Raven Press, New York, pp 813-822
21. Zhou HH, Anthony LB, Wood AJJ, Wilkinson GR (1990) Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol 30: 471-475
22. 1 mutation of CYP2C19 and gene dose. Br J Clin Pharmacol 45: 27-29
23. Bajpai M, Roskos LK, Shen DD, Levy RL (1996) Roles of cytochrome P4502C9 and P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 24: 1401-1403
24. Krecic ME, Shepard DR, Chang T-H, Collins J, Gerber N (1995) Stereoselective metabolism of phenytoin by hepatic microsomes and human CYP2C9 and CYP2C18 expressed in yeast. ISSX Proc 8: 37